EP1226250A2 - Gpcr-kd5 polypeptide und dns sequenzen davon - Google Patents

Gpcr-kd5 polypeptide und dns sequenzen davon

Info

Publication number: EP1226250A2
Authority: EP; European Patent Office
Prior art keywords: polypeptide; polynucleotide; sequence; seq; identity
Prior art date: 1999-11-03
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP00983092A

Other languages

English (en)

French (fr)

Inventor

Klaus DÜCKER

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Merck Patent GmbH

Original Assignee

Merck Patent GmbH

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-11-03

Filing date

2000-10-26

Publication date

2002-07-31

2000-10-26 Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH

2000-10-26 Priority to EP00983092A priority Critical patent/EP1226250A2/de

2002-07-31 Publication of EP1226250A2 publication Critical patent/EP1226250A2/de

Status Withdrawn legal-status Critical Current

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 232
102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 227
229920001184 polypeptide Polymers 0.000 title claims abstract description 225
108091028043 Nucleic acid sequence Proteins 0.000 title description 11
108091033319 polynucleotide Proteins 0.000 claims abstract description 139
102000040430 polynucleotide Human genes 0.000 claims abstract description 139
239000002157 polynucleotide Substances 0.000 claims abstract description 138
238000000034 method Methods 0.000 claims abstract description 76
210000004027 cell Anatomy 0.000 claims description 64
125000003729 nucleotide group Chemical group 0.000 claims description 38
239000002773 nucleotide Substances 0.000 claims description 37
108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 31
150000001875 compounds Chemical class 0.000 claims description 28
239000012634 fragment Substances 0.000 claims description 28
230000014509 gene expression Effects 0.000 claims description 27
238000012216 screening Methods 0.000 claims description 22
239000000203 mixture Substances 0.000 claims description 20
230000027455 binding Effects 0.000 claims description 19
230000000694 effects Effects 0.000 claims description 19
238000004519 manufacturing process Methods 0.000 claims description 12
108020004999 messenger RNA Proteins 0.000 claims description 12
230000004913 activation Effects 0.000 claims description 10
108020001507 fusion proteins Proteins 0.000 claims description 10
102000037865 fusion proteins Human genes 0.000 claims description 10
239000000523 sample Substances 0.000 claims description 10
230000008569 process Effects 0.000 claims description 9
238000009396 hybridization Methods 0.000 claims description 8
230000000295 complement effect Effects 0.000 claims description 7
238000001514 detection method Methods 0.000 claims description 6
239000012528 membrane Substances 0.000 claims description 6
230000005764 inhibitory process Effects 0.000 claims description 5
108060003951 Immunoglobulin Proteins 0.000 claims description 4
102000018358 immunoglobulin Human genes 0.000 claims description 4
238000010561 standard procedure Methods 0.000 claims description 4
239000000126 substance Substances 0.000 claims description 4
238000012286 ELISA Assay Methods 0.000 claims description 3
210000000170 cell membrane Anatomy 0.000 claims description 3
238000002156 mixing Methods 0.000 claims description 2
238000012360 testing method Methods 0.000 claims description 2
239000013604 expression vector Substances 0.000 claims 2
238000012258 culturing Methods 0.000 claims 1
239000001963 growth medium Substances 0.000 claims 1
238000003556 assay Methods 0.000 abstract description 11
238000010188 recombinant method Methods 0.000 abstract description 3
108090000623 proteins and genes Proteins 0.000 description 54
102000005962 receptors Human genes 0.000 description 49
108020003175 receptors Proteins 0.000 description 49
108020004414 DNA Proteins 0.000 description 29
239000003446 ligand Substances 0.000 description 24
102000004169 proteins and genes Human genes 0.000 description 23
102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 22
108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 22
235000018102 proteins Nutrition 0.000 description 22
235000001014 amino acid Nutrition 0.000 description 21
229940024606 amino acid Drugs 0.000 description 19
150000001413 amino acids Chemical class 0.000 description 19
201000010099 disease Diseases 0.000 description 19
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
241001465754 Metazoa Species 0.000 description 16
239000002299 complementary DNA Substances 0.000 description 16
239000013615 primer Substances 0.000 description 16
239000000556 agonist Substances 0.000 description 15
125000003275 alpha amino acid group Chemical group 0.000 description 15
108091006027 G proteins Proteins 0.000 description 12
102000030782 GTP binding Human genes 0.000 description 12
108091000058 GTP-Binding Proteins 0.000 description 12
239000005557 antagonist Substances 0.000 description 12
210000001519 tissue Anatomy 0.000 description 12
239000013598 vector Substances 0.000 description 12
-1 e.g. Proteins 0.000 description 9
238000005516 engineering process Methods 0.000 description 9
102000039446 nucleic acids Human genes 0.000 description 9
108020004707 nucleic acids Proteins 0.000 description 9
150000007523 nucleic acids Chemical class 0.000 description 9
239000000047 product Substances 0.000 description 9
102000004190 Enzymes Human genes 0.000 description 8
108090000790 Enzymes Proteins 0.000 description 8
229940088598 enzyme Drugs 0.000 description 8
230000004048 modification Effects 0.000 description 8
238000012986 modification Methods 0.000 description 8
238000006467 substitution reaction Methods 0.000 description 8
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 7
108020004635 Complementary DNA Proteins 0.000 description 7
230000003321 amplification Effects 0.000 description 7
239000011575 calcium Substances 0.000 description 7
229910052791 calcium Inorganic materials 0.000 description 7
238000009472 formulation Methods 0.000 description 7
230000002068 genetic effect Effects 0.000 description 7
238000003780 insertion Methods 0.000 description 7
230000037431 insertion Effects 0.000 description 7
238000003199 nucleic acid amplification method Methods 0.000 description 7
210000000287 oocyte Anatomy 0.000 description 7
230000026731 phosphorylation Effects 0.000 description 7
238000006366 phosphorylation reaction Methods 0.000 description 7
102000030621 adenylate cyclase Human genes 0.000 description 6
108060000200 adenylate cyclase Proteins 0.000 description 6
230000004071 biological effect Effects 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
238000012217 deletion Methods 0.000 description 6
230000037430 deletion Effects 0.000 description 6
239000000284 extract Substances 0.000 description 6
230000001404 mediated effect Effects 0.000 description 6
230000009261 transgenic effect Effects 0.000 description 6
108700028369 Alleles Proteins 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
230000008827 biological function Effects 0.000 description 5
230000002759 chromosomal effect Effects 0.000 description 5
229940088597 hormone Drugs 0.000 description 5
239000005556 hormone Substances 0.000 description 5
230000035772 mutation Effects 0.000 description 5
238000000746 purification Methods 0.000 description 5
230000004044 response Effects 0.000 description 5
230000019491 signal transduction Effects 0.000 description 5
229960005486 vaccine Drugs 0.000 description 5
102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
241000124008 Mammalia Species 0.000 description 4
241000700605 Viruses Species 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
238000005755 formation reaction Methods 0.000 description 4
230000028993 immune response Effects 0.000 description 4
239000000463 material Substances 0.000 description 4
239000000243 solution Substances 0.000 description 4
241000894007 species Species 0.000 description 4
238000001712 DNA sequencing Methods 0.000 description 3
108091034117 Oligonucleotide Proteins 0.000 description 3
102000006382 Ribonucleases Human genes 0.000 description 3
108010083644 Ribonucleases Proteins 0.000 description 3
240000004808 Saccharomyces cerevisiae Species 0.000 description 3
241000269370 Xenopus <genus> Species 0.000 description 3
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
239000002253 acid Substances 0.000 description 3
230000003213 activating effect Effects 0.000 description 3
238000007792 addition Methods 0.000 description 3
230000004075 alteration Effects 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
125000004122 cyclic group Chemical group 0.000 description 3
230000001086 cytosolic effect Effects 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
238000003745 diagnosis Methods 0.000 description 3
239000012636 effector Substances 0.000 description 3
230000006870 function Effects 0.000 description 3
238000002825 functional assay Methods 0.000 description 3
230000004927 fusion Effects 0.000 description 3
238000013537 high throughput screening Methods 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
230000003834 intracellular effect Effects 0.000 description 3
230000011987 methylation Effects 0.000 description 3
238000007069 methylation reaction Methods 0.000 description 3
238000000520 microinjection Methods 0.000 description 3
239000013612 plasmid Substances 0.000 description 3
230000004481 post-translational protein modification Effects 0.000 description 3
230000005855 radiation Effects 0.000 description 3
230000028327 secretion Effects 0.000 description 3
239000000758 substrate Substances 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
238000001890 transfection Methods 0.000 description 3
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
230000005730 ADP ribosylation Effects 0.000 description 2
108091026890 Coding region Proteins 0.000 description 2
241000699800 Cricetinae Species 0.000 description 2
102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 2
108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 2
102000053602 DNA Human genes 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
208000012902 Nervous system disease Diseases 0.000 description 2
208000025966 Neurological disease Diseases 0.000 description 2
238000000636 Northern blotting Methods 0.000 description 2
208000028017 Psychotic disease Diseases 0.000 description 2
238000012300 Sequence Analysis Methods 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
238000001042 affinity chromatography Methods 0.000 description 2
125000000539 amino acid group Chemical group 0.000 description 2
238000013459 approach Methods 0.000 description 2
238000003491 array Methods 0.000 description 2
208000006673 asthma Diseases 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
210000000349 chromosome Anatomy 0.000 description 2
230000014107 chromosome localization Effects 0.000 description 2
238000010367 cloning Methods 0.000 description 2
238000004132 cross linking Methods 0.000 description 2
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
238000012912 drug discovery process Methods 0.000 description 2
238000002001 electrophysiology Methods 0.000 description 2
230000007831 electrophysiology Effects 0.000 description 2
238000004520 electroporation Methods 0.000 description 2
230000002538 fungal effect Effects 0.000 description 2
230000013595 glycosylation Effects 0.000 description 2
238000006206 glycosylation reaction Methods 0.000 description 2
108091008039 hormone receptors Proteins 0.000 description 2
210000003917 human chromosome Anatomy 0.000 description 2
210000004408 hybridoma Anatomy 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
239000000543 intermediate Substances 0.000 description 2
238000002955 isolation Methods 0.000 description 2
238000000670 ligand binding assay Methods 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
210000004962 mammalian cell Anatomy 0.000 description 2
238000013507 mapping Methods 0.000 description 2
239000003550 marker Substances 0.000 description 2
238000003752 polymerase chain reaction Methods 0.000 description 2
102000054765 polymorphisms of proteins Human genes 0.000 description 2
230000001323 posttranslational effect Effects 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
239000002987 primer (paints) Substances 0.000 description 2
238000012545 processing Methods 0.000 description 2
238000000159 protein binding assay Methods 0.000 description 2
230000009145 protein modification Effects 0.000 description 2
230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
238000007423 screening assay Methods 0.000 description 2
230000003248 secreting effect Effects 0.000 description 2
235000004400 serine Nutrition 0.000 description 2
150000003355 serines Chemical class 0.000 description 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
150000003384 small molecules Chemical class 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
230000002123 temporal effect Effects 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
230000014616 translation Effects 0.000 description 2
238000013519 translation Methods 0.000 description 2
238000010798 ubiquitination Methods 0.000 description 2
230000034512 ubiquitination Effects 0.000 description 2
241001515965 unidentified phage Species 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
241000228212 Aspergillus Species 0.000 description 1
241000972773 Aulopiformes Species 0.000 description 1
244000063299 Bacillus subtilis Species 0.000 description 1
235000014469 Bacillus subtilis Nutrition 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
208000020925 Bipolar disease Diseases 0.000 description 1
241000269420 Bufonidae Species 0.000 description 1
208000032841 Bulimia Diseases 0.000 description 1
206010006550 Bulimia nervosa Diseases 0.000 description 1
239000002126 C01EB10 - Adenosine Substances 0.000 description 1
102000055006 Calcitonin Human genes 0.000 description 1
108060001064 Calcitonin Proteins 0.000 description 1
206010007556 Cardiac failure acute Diseases 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
102000019034 Chemokines Human genes 0.000 description 1
108010012236 Chemokines Proteins 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
101150074155 DHFR gene Proteins 0.000 description 1
239000003155 DNA primer Substances 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
206010012218 Delirium Diseases 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
102000015554 Dopamine receptor Human genes 0.000 description 1
108050004812 Dopamine receptor Proteins 0.000 description 1
241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
208000012661 Dyskinesia Diseases 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
102000002045 Endothelin Human genes 0.000 description 1
108050009340 Endothelin Proteins 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
102000009109 Fc receptors Human genes 0.000 description 1
108010087819 Fc receptors Proteins 0.000 description 1
102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
241000700662 Fowlpox virus Species 0.000 description 1
206010017533 Fungal infection Diseases 0.000 description 1
HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical group C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
108010093488 His-His-His-His-His-His Proteins 0.000 description 1
241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
208000001953 Hypotension Diseases 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
208000026350 Inborn Genetic disease Diseases 0.000 description 1
229930010555 Inosine Natural products 0.000 description 1
UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
102000004310 Ion Channels Human genes 0.000 description 1
108090000862 Ion Channels Proteins 0.000 description 1
102000002397 Kinins Human genes 0.000 description 1
108010093008 Kinins Proteins 0.000 description 1
108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
108090001090 Lectins Proteins 0.000 description 1
102000004856 Lectins Human genes 0.000 description 1
241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
208000031888 Mycoses Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
108050002069 Olfactory receptors Proteins 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
102000010175 Opsin Human genes 0.000 description 1
108050001704 Opsin Proteins 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
102000003923 Protein Kinase C Human genes 0.000 description 1
108090000315 Protein Kinase C Proteins 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
208000010362 Protozoan Infections Diseases 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
108091005682 Receptor kinases Proteins 0.000 description 1
102000004330 Rhodopsin Human genes 0.000 description 1
108090000820 Rhodopsin Proteins 0.000 description 1
AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
208000036623 Severe mental retardation Diseases 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
241000256248 Spodoptera Species 0.000 description 1
241000295644 Staphylococcaceae Species 0.000 description 1
241000187747 Streptomyces Species 0.000 description 1
241000701093 Suid alphaherpesvirus 1 Species 0.000 description 1
108091036066 Three prime untranslated region Proteins 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
108020004566 Transfer RNA Proteins 0.000 description 1
102000014384 Type C Phospholipases Human genes 0.000 description 1
108010079194 Type C Phospholipases Proteins 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
108091023045 Untranslated Region Proteins 0.000 description 1
206010046555 Urinary retention Diseases 0.000 description 1
241000700618 Vaccinia virus Species 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
229960005305 adenosine Drugs 0.000 description 1
UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical class C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000001800 adrenalinergic effect Effects 0.000 description 1
239000000464 adrenergic agent Substances 0.000 description 1
230000032683 aging Effects 0.000 description 1
230000007815 allergy Effects 0.000 description 1
230000009435 amidation Effects 0.000 description 1
238000007112 amidation reaction Methods 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
238000012870 ammonium sulfate precipitation Methods 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
238000005571 anion exchange chromatography Methods 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
230000010516 arginylation Effects 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical group N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
238000011888 autopsy Methods 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
230000006287 biotinylation Effects 0.000 description 1
238000007413 biotinylation Methods 0.000 description 1
208000028683 bipolar I disease Diseases 0.000 description 1
210000002459 blastocyst Anatomy 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
238000006664 bond formation reaction Methods 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
230000001593 cAMP accumulation Effects 0.000 description 1
230000003491 cAMP production Effects 0.000 description 1
238000010804 cDNA synthesis Methods 0.000 description 1
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
229960004015 calcitonin Drugs 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
238000005277 cation exchange chromatography Methods 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
238000012875 competitive assay Methods 0.000 description 1
230000009137 competitive binding Effects 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000000875 corresponding effect Effects 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
229960003067 cystine Drugs 0.000 description 1
108010041898 cytomegalovirus receptor Proteins 0.000 description 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
230000017858 demethylation Effects 0.000 description 1
238000010520 demethylation reaction Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000000586 desensitisation Methods 0.000 description 1
238000013461 design Methods 0.000 description 1
229960002086 dextran Drugs 0.000 description 1
229960000633 dextran sulfate Drugs 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
230000029087 digestion Effects 0.000 description 1
229960003638 dopamine Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000007876 drug discovery Methods 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
210000001671 embryonic stem cell Anatomy 0.000 description 1
210000002257 embryonic structure Anatomy 0.000 description 1
210000002472 endoplasmic reticulum Anatomy 0.000 description 1
230000009762 endothelial cell differentiation Effects 0.000 description 1
ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
238000012869 ethanol precipitation Methods 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
238000001400 expression cloning Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
238000001125 extrusion Methods 0.000 description 1
229940028334 follicle stimulating hormone Drugs 0.000 description 1
230000022244 formylation Effects 0.000 description 1
238000006170 formylation reaction Methods 0.000 description 1
239000003205 fragrance Substances 0.000 description 1
239000000446 fuel Substances 0.000 description 1
YFHXZQPUBCBNIP-UHFFFAOYSA-N fura-2 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=3OC(=CC=3C=2)C=2OC(=CN=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 YFHXZQPUBCBNIP-UHFFFAOYSA-N 0.000 description 1
230000006251 gamma-carboxylation Effects 0.000 description 1
239000000499 gel Substances 0.000 description 1
238000003209 gene knockout Methods 0.000 description 1
208000016361 genetic disease Diseases 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
210000002816 gill Anatomy 0.000 description 1
150000002333 glycines Chemical group 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
150000003278 haem Chemical group 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
238000012188 high-throughput screening assay Methods 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
210000004754 hybrid cell Anatomy 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
125000001165 hydrophobic group Chemical group 0.000 description 1
238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
238000012872 hydroxylapatite chromatography Methods 0.000 description 1
230000033444 hydroxylation Effects 0.000 description 1
238000005805 hydroxylation reaction Methods 0.000 description 1
230000036543 hypotension Effects 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
238000002513 implantation Methods 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
229960003786 inosine Drugs 0.000 description 1
230000031146 intracellular signal transduction Effects 0.000 description 1
230000004068 intracellular signaling Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000026045 iodination Effects 0.000 description 1
238000006192 iodination reaction Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
238000005304 joining Methods 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
239000002523 lectin Substances 0.000 description 1
230000029226 lipidation Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000011068 loading method Methods 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
238000002493 microarray Methods 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
230000003551 muscarinic effect Effects 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
230000007498 myristoylation Effects 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
239000013642 negative control Substances 0.000 description 1
239000003176 neuroleptic agent Substances 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000037361 pathway Effects 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
210000001322 periplasm Anatomy 0.000 description 1
235000008729 phenylalanine Nutrition 0.000 description 1
229940080469 phosphocellulose Drugs 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000013823 prenylation Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
229940043131 pyroglutamate Drugs 0.000 description 1
230000006340 racemization Effects 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000000163 radioactive labelling Methods 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
108091006082 receptor inhibitors Proteins 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
238000003757 reverse transcription PCR Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000007363 ring formation reaction Methods 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
235000019515 salmon Nutrition 0.000 description 1
201000000980 schizophrenia Diseases 0.000 description 1
230000007017 scission Effects 0.000 description 1
210000002265 sensory receptor cell Anatomy 0.000 description 1
229940076279 serotonin Drugs 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
230000019635 sulfation Effects 0.000 description 1
238000005670 sulfation reaction Methods 0.000 description 1
238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
230000008685 targeting Effects 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
235000008521 threonine Nutrition 0.000 description 1
150000003588 threonines Chemical class 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
238000010361 transduction Methods 0.000 description 1
230000026683 transduction Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
229940038773 trisodium citrate Drugs 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
235000002374 tyrosine Nutrition 0.000 description 1
150000003668 tyrosines Chemical class 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
230000009452 underexpressoin Effects 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
238000010200 validation analysis Methods 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
230000008673 vomiting Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1
238000001262 western blot Methods 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Definitions

G-proteins themselves, effector proteins, e.g., phospholipase C, adenyl cyclase, and phosphodiesterase, and actuator proteins, e.g., protein kinase A and protein kinase C (Simon, M.I., et al., Science, 1991 , 252:802-8).
effector proteins e.g., phospholipase C, adenyl cyclase, and phosphodiesterase
actuator proteins e.g., protein kinase A and protein kinase C (Simon, M.I., et al., Science, 1991 , 252:802-8).
G-protein coupled receptors can be intracellularly coupled by heterot meric G-proteins to various intracellular enzymes, ion channels and transporters (see, Johnson et al., Endoc. Rev., 1989, 10:317-331)
Different G-protein a-subunits preferentially stimulate particular effectors to modulate various biological functions in a cell.
Phosphorylation of cytoplasmic residues of G- protein coupled receptors have been identified as an important mechanism for the regulation of G-protein coupling of some G-protein coupied receptors.
G-protein coupled receptors are found in numerous sites within a mammalian host.
the present invention relates to GPCR_KD5, in particular GPCR_KD5 polypeptides and GPCR_KD5 polynucleotides, recombinant materials and methods for their production.
Such polypeptides and polynucleotides are of interest in relation to methods of treatment of certain diseases, including, but not limited to, infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; diabetes, obesity; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; stroke; ulcers; asthma; allergies; benign prostatic hypertrophy; migraine; vomiting; psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, depression, delirium, dementia, and severe mental retardation; and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome, hereinafter
Polypeptides of the present invention can be prepared in any suitable manner, for instance by isolation form naturally occuring sources, from genetically engineered host cells comprising expression systems (vide infra) or by chemical synthesis, using for instance automated peptide synthesisers, or a combination of such methods.
Means for preparing such polypeptides are well understood in the art.
Screening kits for use in the above described methods form a further aspect of the present invention.
Such screening kits comprise:
an average of up to 5 in every 100 of the amino acids in the reference sequence may be deleted, substituted or inserted, or any combination thereof, as hereinbefore described.
“Homolog” is a generic term used in the art to indicate a polynucleotide or polypeptide sequence possessing a high degree of sequence relatedness to a reference sequence. Such relatedness may be quantified by determining the degree of identity and/or similarity between the two sequences as hereinbefore defined. Falling within this generic term are the terms “ortholog”, and “paralog”. "Ortholog” refers to a polynucleotide or polypeptide that is the functional equivalent of the polynucleotide or polypeptide in another species. "Paralog” refers to a polynucleotideor polypeptide that within the same species which is functionally similar.

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Gastroenterology & Hepatology (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Cell Biology (AREA)
Immunology (AREA)
Toxicology (AREA)
Zoology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

EP00983092A 1999-11-03 2000-10-26 Gpcr-kd5 polypeptide und dns sequenzen davon Withdrawn EP1226250A2 (de)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
EP00983092A EP1226250A2 (de)	1999-11-03	2000-10-26	Gpcr-kd5 polypeptide und dns sequenzen davon

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
EP99121786		1999-11-03
EP99121786		1999-11-03
PCT/EP2000/010564 WO2001032864A2 (en)	1999-11-03	2000-10-26	Gpcr-kd5 polypeptides and dna sequences thereof
EP00983092A EP1226250A2 (de)	1999-11-03	2000-10-26	Gpcr-kd5 polypeptide und dns sequenzen davon

Publications (1)

Publication Number	Publication Date
EP1226250A2 true EP1226250A2 (de)	2002-07-31

Family

ID=8239324

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP00983092A Withdrawn EP1226250A2 (de)	1999-11-03	2000-10-26	Gpcr-kd5 polypeptide und dns sequenzen davon

Country Status (4)

Country	Link
EP (1)	EP1226250A2 (de)
JP (1)	JP2003513629A (de)
CA (1)	CA2388308A1 (de)
WO (1)	WO2001032864A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7816492B2 (en)	1998-11-20	2010-10-19	Arena Pharmaceuticals, Inc.	Human G protein-coupled receptors
US20030017528A1 (en)	1998-11-20	2003-01-23	Ruoping Chen	Human orphan G protein-coupled receptors
USRE42190E1 (en)	1998-11-20	2011-03-01	Arena Pharmaceuticals, Inc.	Method of identifying a compound for inhibiting or stimulating human G protein-coupled receptors
EP1287133B1 (de) *	2000-05-18	2006-12-13	Bayer HealthCare AG	Regulation eines menschlichen dopamine-ähnlichen g-protein gekoppelten rezeptor.
EP1338651B9 (de) *	2000-12-01	2007-05-09	Astellas Pharma Inc.	Verfahren zum screening von diabetes-heilverfahren
US7083933B1 (en)	2003-05-09	2006-08-01	Prosidion Limited	Methods for identification of modulators of OSGPR116 activity
BRPI0817211A2 (pt)	2007-09-20	2017-05-16	Irm Llc	composto composições como moduladores da atividade de gpr119

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK1584683T3 (da) *	1998-11-20	2007-10-29	Arena Pharm Inc	Human G-protein-koblet orphan receptor RUP3
US6221660B1 (en) *	1999-02-22	2001-04-24	Synaptic Pharmaceutical Corporation	DNA encoding SNORF25 receptor

2000
- 2000-10-26 EP EP00983092A patent/EP1226250A2/de not_active Withdrawn
- 2000-10-26 CA CA002388308A patent/CA2388308A1/en not_active Abandoned
- 2000-10-26 WO PCT/EP2000/010564 patent/WO2001032864A2/en not_active Ceased
- 2000-10-26 JP JP2001535546A patent/JP2003513629A/ja active Pending

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0132864A2 *

Also Published As

Publication number	Publication date
WO2001032864A2 (en)	2001-05-10
CA2388308A1 (en)	2001-05-10
JP2003513629A (ja)	2003-04-15
WO2001032864A3 (en)	2001-12-06

Legal Events

Date	Code	Title	Description
2002-06-14	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2002-07-31	17P	Request for examination filed	Effective date: 20020314
2002-07-31	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
2004-09-15	17Q	First examination report despatched	Effective date: 20040803
2005-06-10	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2005-07-27	18D	Application deemed to be withdrawn	Effective date: 20041214

Publication	Publication Date	Title
WO2001014577A1 (en)	2001-03-01	Molecular cloning of a galanin like 7tm receptor (axor40)
WO2001016159A1 (en)	2001-03-08	Gpcr, theant
EP1203023A1 (de)	2002-05-08	Pgpcr-3 polypeptide und dns-sequenze davon
EP1226250A2 (de)	2002-07-31	Gpcr-kd5 polypeptide und dns sequenzen davon
US20070207506A1 (en)	2007-09-06	G-protein coupled receptor and DNA sequences thereof
WO2001053308A1 (en)	2001-07-26	Cloning of a monkey 7tm receptor (axor8)
WO2001042486A1 (en)	2001-06-14	Axor12
US20040071695A1 (en)	2004-04-15	Novel g-protein coupled receptor
EP1226247A1 (de)	2002-07-31	Polypeptid- und polynukleotidsequenzen eines humanen, gpr27-ähnlichen g-protein gekoppelten rezeptors
AU2001283930B2 (en)	2007-04-19	Novel g-protein coupled receptor
AU2001281836B2 (en)	2006-10-26	A g-protein coupled receptor
US20050054034A1 (en)	2005-03-10	Thyrotropin-releasing hormone receptor-like gpcr(gprfwki)
WO2001053337A1 (en)	2001-07-26	Human 7 transmembrane receptor axor33
WO2001064836A2 (en)	2001-09-07	Cloning of a gpr38 variant
US20060154244A1 (en)	2006-07-13	Novel g-protein coupled receptor
US20040106149A1 (en)	2004-06-03	Novel gpcr hfrbn63
EP1232265A2 (de)	2002-08-21	An ein g-protein gekoppelter rezeptor, htogh35
WO2001025280A1 (en)	2001-04-12	Paul, a g-protein coupled receptor
WO2001068665A1 (en)	2001-09-20	Human histamine h3 gene variant-1
WO2001061003A1 (en)	2001-08-23	The human homologue of flamingo
AU2001281836A1 (en)	2002-03-21	A g-protein coupled receptor
WO2001036484A1 (en)	2001-05-25	New olfactory receptor polypeptides and dna sequences thereof
WO2001014410A1 (en)	2001-03-01	Cloning of a pafr like 7tm receptor (axor11)
AU2001283930A1 (en)	2002-05-02	Novel g-protein coupled receptor
WO2001016177A1 (en)	2001-03-08	Mouse g-protein coupled 7 transmembrane receptor, canoman